Innovation in Quantitative Medicine Summit

September 1, 2026
12:00 pm – 4:00 pm ET

Virtual Public Meeting

Background and Objectives

This virtual public meeting, co-convened by the Duke-Margolis Institute for Health Policy and the U.S. Food and Drug Administration's (FDA) Quantitative Medicine Center of Excellence (QM CoE), will inform the establishment of the Quantitative Medicine Innovation Network (QMIN). This network will be a cross-sector collaboration to fundamentally transform drug development and clinical care through quantitative medicine (QM). Participants will share lessons learned from successful collaborative models in drug development and will discuss potential governance structures, incentive frameworks, and resource-sharing mechanisms that will sustain meaningful stakeholder participation. Stakeholders will suggest strategies to establish a sustainable coordinated network and consider priority scientific gaps and regulatory goals that the QMIN is uniquely positioned to address.

Agenda

12:00 PM **Welcome and Introduction**

12:05 PM **Opening Remarks**

12:15 PM **Introducing the Quantitative Medicine Innovation Network**

The QM CoE leadership will give an update on their ongoing activities that support the advancement of QM approaches across CDER and share background on the establishment of the QMIN.

12:30 PM **Session 1.1: Transforming Drug Development and Clinical Practice with QM**

Presenters will share perspectives on where QM approaches transformed drug development or clinical practice and describe challenges and opportunities for further QM advancements.

1:00 PM **Session 1.2: Transforming Drug Development and Clinical Practice with QM**

Participants will consider where QM approaches can be most transformative in drug development and clinical practice and highlight actionable opportunities unique to the QMIN. Panelists will discuss priority domains and selection criteria for use cases, focusing on challenges in unmet needs, tools, standards, or infrastructure where coordinated network activity can deliver high-impact solutions.

1:45 PM **Break**

DRAFT

2:00 PM **Session 2.1: Building and Sustaining a Collaborative Ecosystem**

Presenters will reflect on their experience from established collaborative networks and share lessons learned in building and sustaining multi-stakeholder collaborations.

2:30 PM **Session 2.2: Building and Sustaining a Collaborative Ecosystem**

Panelists will consider foundational needs for building a network model capable of sustaining transformative opportunities for the QM community. They will examine the QMIN's role relative to existing collaborative efforts, potential mechanisms for resource sharing, modes of collaboration, and how the QMIN can incentivize stakeholder engagement to sustain meaningful impact.

3:00 PM **Break**

3:15 PM **Session 3: Charting a Path Forward for Innovation in Quantitative Medicine**
Thought leaders will reflect on the suggestions covered in previous sessions and consider the next steps for the QMIN. The participants will discuss the goals and priorities that could guide the network to achieve measurable progress.

3:55 PM **Concluding Remarks**

4:00 PM **Adjournment**

Funding Acknowledgement

This project is supported by the Food and Drug Administration (FDA) of the U.S. Department of Health and Human Services (HHS) as part of a financial assistance award U19FD006602 totaling $5,192,495 with 100 percent funded by FDA/HHS. The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement, by FDA/HHS, or the U.S. Government.

DRAFT